Eden Research plc

January 19, 2011 09:30 ET

Debt conversion, exercise of warrants, Directors' Interests and grant of options

                                                                                       19 January 2011
                                           EDEN RESEARCH PLC
                                         ("Eden" or "Company")

           Debt conversion, exercise of warrants, Directors' Interests and grant of options

Eden  Research  plc, a leading UK agrochemical development company, is pleased to  announce  that  GBP
550,000 of long term debt has been converted into 4,400,000 ordinary shares in the Company at a  price
of 12.5p.

Also, 1,557,849 warrants have been exercised at a price of 13p.

Following this debt conversion and exercise of warrants, Eden has 72,986,200 ordinary shares in issue,
of  which the Directors are interested in a total of 1,651,893 ordinary shares, representing 2.27  per
cent of the Company's enlarged issued share capital, as follows:

Director             No of shares held      % of enlarged share capital
A Abrey                        155,940                             0.21
K Brooks                       931,010                             1.28
B Gill                         385,848                             0.53
C Newitt                       179,095                             0.25

In  addition to this, on 17 January 2011, the Company granted options to the following directors under
the terms of its Share Option Scheme:

Director                 Share options granted       Total options held
A Abrey                              1,050,000                1,500,000
K Brooks                             1,100,000                2,500,000
B Gill                                 500,000                  600,000
C Newitt                               450,000                  600,000

The new options can be exercised at a price of 13 pence per share at any time up to 16 January 2016.
The Directors of Eden are responsible for the contents of this announcement.


Eden Research plc                                                        01993 862761
Clive Newitt, Managing Director

St Helens Capital Partners LLP                                           020 7368 6959
Mark Anwyl


Eden's strategy is focused on the development and commercialisation of its terpene-based encapsulation
technology  for  agricultural  and  non-agricultural  uses  through  appropriate  regional  or  global

Terpenes  are  natural  compounds which function as defence mechanisms in many plant  groups  and  are
released in response to infection, attack by pests, stress or mechanical injury. Terpenes are  already
widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically,  terpenes  have  had  limited commercial use in the agrochemical  sector  due  to  their
volatility,  phytotoxicity and poor solubility. Eden's platform encapsulation technology provides  the
unique,  natural  solution to these problems and enables terpenes to be used  as  effective,  low-risk

Contact Information

  • Eden Research plc